Summary:
In adults with type 2 diabetes, co-infusion of exenatide and glucagon significantly increased myocardial glucose uptake and improved diastolic function compared to saline or glucagon infusion alone, though it was associated with no notable adverse effects reported in this study.
| PICO | Description |
|---|---|
| Population | Eight adults with type 2 diabetes (mean age 52 ± 12 years; BMI 31 ± 4 kg/m²). |
| Intervention | Co-infusion of exenatide (loading dose 50 ng/min for 30 min followed by 25 ng/min) and glucagon (12.5 ng/kg/min). |
| Comparison | Infusion of 0.9% saline or glucagon alone. |
| Outcome | Significant increase in myocardial glucose uptake from a median of 9.2×10⁻³ µmol/g/min (saline) to 20×10⁻³ µmol/g/min with exenatide:glucagon (P < 0.05). Diastolic function improved as indicated by an increase in peak diastolic circumferential strain rate. Longitudinal strain increased numerically without statistical significance. |
Source: James Goodman, et al. “Exenatide and glucagon co-infusion increases myocardial glucose uptake and improves markers of diastolic dysfunction in adults with type 2 diabetes.” Read article here.
